| Publication pre 1991 |
| 1. Chen DX, Schwartz PE, Li XG, Yang Z. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses. Obstetrics and gynecology. 1988;72(1):23‐7. |
| 2. Einhorn N, Bast RC, Jr, Knapp RC, Tjernberg B, Zurawski VR, Jr. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer. Obstetrics and gynecology. 1986;67(3):414‐6. |
| 3. Einhorn N, Knapp RC, Bast RC, Zurawski VR. Ca 125 Assay Used in Conjunction with Ca 15–3 and Tag‐72 Assays for Discrimination Between Malignant and Non‐Malignant Diseases of the Ovary. Acta Oncologica. 1989;28(5):655‐7. |
| 4. FINKLER NJ, BENACERRAF B, LAVIN PT, WOJCIECHOWSKI C, KNAPP RC. Comparison of Serum CA 125, Clinical Impression, and Ultrasound in the Preoperative Evaluation of Ovarian Masses. Obstetrics & Gynecology. 1988;72(4):659‐64. |
| 5. Gadducci A, Capriello P, Bartolini T, Barale E, Cappelli N, Facchini V, et al. The association of ultrasonography and CA‐125 test in the preoperative evaluation of ovarian carcinoma. European Journal of Gynaecological Oncology. 1988;9(5):373‐6. |
| 6. Hawkins RE, Roberts K, Wiltshaw E, Mundy J, McCready VR. The clinical correlates of serum CA125 in 169 patients with epithelial ovarian carcinoma. Br J Cancer. 1989;60(4):634‐7. |
| 7. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol. 1990;97(10):922‐9. |
| 8. Malkasian GD, Jr, Knapp RC, Lavin PT, Zurawski VR, Jr, Podratz KC, Stanhope CR, et al. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. American journal of obstetrics and gynecology. 1988;159(2):341‐6. |
| 9. Mogensen O, Mogensen B, Jakobsen A. CA 125 in the diagnosis of pelvic masses. European Journal of Cancer and Clinical Oncology. 1989;25(8):1187‐90. |
| 10. O'Connell GJ, Ryan E, Murphy KJ, Prefontaine M. Predictive value of CA 125 for ovarian carcinoma in patients presenting with pelvic masses. Obstetrics and gynecology. 1987;70(6):930‐2. |
| 11. Patsner B, Mann WJ. The value of preoperative serum CA 125 levels in patients with a pelvic mass. American journal of obstetrics and gynecology. 1988;159(4):873‐6. |
| 12. SOPER JT, HUNTER VJ, DALY L, TANNER M, CREASMAN WT, BAST RCJ. Preoperative Serum Tumor‐Associated Antigen Levels in Women With Pelvic Masses. Obstetrics & Gynecology. 1990;75(2):249‐54. |
| 13. Vasilev SA, Schlaerth JB, Campeau J, Morrow CP. Serum CA 125 levels in preoperative evaluation of pelvic masses. Obstetrics and Gynecology. 1988;71(5):751‐6. |
| 14. Yedema C, Massuger L, Hilgers J, Servaas J, Poels L, Thomas C, et al. Pre‐operative discrimination between benign and malignant ovarian tumors using a combination of CA125 and CA15.3 serum assays. International journal of cancer Supplement = Journal international du cancer Supplement. 1988;3:61‐7. |
| 15. Zurawski VR, Jr, Knapp RC, Einhorn N, Kenemans P, Mortel R, Ohmi K, et al. An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma. Gynecol Oncol. 1988;30(1):7‐14. |
